 |
|
|
| |
8 weeks of Glecaprevir/pibrentasvir is effective and
well tolerated in non-GT3 HCV patients with cirrhosis
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Marra F, Boyle A, McDonald N ,Priest M, Morris J, Peters E, Barclay ST: NHS Greater Glasgow and Clyde
|
| |
|
|
|
|
|
